Correspondence

References

• Myers RA, DeFazio A, Kelly MP. Chronic carbon monoxide exposure: a clinical syndrome detected by neuropsychological tests. J Clin Psychol 1998; 54: 555–567
   PubMed Web of Science ®Google Scholar
• Choi IS. Parkinsonism after carbon monoxide poisoning. Eur Neurol 2002; 48: 30–33
   PubMed Web of Science ®Google Scholar
• Yoshii F, Kozuma R, Takahashi W, Haida M, Takagi S, Shinohara Y. Magnetic resonance imaging and C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. J Neurol Sci 1998; 160: 87–91
   PubMed Web of Science ®Google Scholar
• Parkinson RB, Hopkins RO, Cleavinger HB, et al. White matter hyperintensities and neuropsychological outcome following carbon monoxide poisoning. Neurology 2002; 58: 1525–1532
   PubMed Web of Science ®Google Scholar
• Hurley RA, Hopkins RO, Bigler ED, Taber KH. Applications of functional imaging to carbon monoxide poisoning. J Neuropsychiatry Clin Neurosci 2001; 13: 157–160
   PubMed Web of Science ®Google Scholar
• Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B. Psycho-pharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73–82
   PubMed Web of Science ®Google Scholar
• Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000; 15: 13–22
   PubMed Web of Science ®Google Scholar
• Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride: a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14: 209–218
   PubMed Web of Science ®Google Scholar
• Curran MP, Perry CM. Spotlight on amisulpride in schizophrenia. CNS Drugs 2002; 16: 207–211
   PubMed Web of Science ®Google Scholar
• Lin C-L, Shiah I-S, Yeh C-B, Wan F-J, Wang T-S. Amisulpride related tic-like symptoms in an adolescent schizophrenic. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 144–146
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Engel R, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180–190
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245
   PubMed Web of Science ®Google Scholar
• Ferracuti S, Sacco R, Lazzari R. Dissociative trance disorder: clinical and Rorschach findings in ten persons reporting demon possession and treated by exorcism. J Pers Assess 1996; 66: 525–539
   PubMed Web of Science ®Google Scholar
• Hale AS, Pinninti NR. Exorcism-resistant ghost possession treated with clopenthixol. Br J Psychiatry 1994; 165: 386–388
   PubMed Web of Science ®Google Scholar
• Elmore JL. Dissociative spectrum disorders in the primary care setting. Prim Care Companion J Clin Psychiatry 2000; 2: 37–41
   PubMedGoogle Scholar
• Mondon K, de Toffol B, Praline J, et al. Psychiatric comorbidity in patients with pseudoseizures: retrospective study conducted in a video-EEG center. Rev Neurol (Paris) 2005; 161: 1061–1069
   PubMed Web of Science ®Google Scholar
• Satoh S, Obata S, Seno E, et al. A case of possessive state with onset influenced by door-to-door sales. Psychiatry Clin Neurosci 1996; 50: 313–316
   PubMed Web of Science ®Google Scholar
• Palenzona S, Meier PJ, Kupferschmidt H, Rauber-Luethy C. The clinical picture of olanzapine poisoning with special reference to fluctuating mental status. J Toxicol Clin Toxicol 2004; 42: 27–32
   PubMed Web of Science ®Google Scholar
• Lim C J, Trevino C, Tampi R. Can olanzapine cause delirium in the elderly?. BMJ 2006; 332: 455–459
   PubMed Web of Science ®Google Scholar
• Singh D. Diagnosis of dementia with Lewy bodies in clinical practice: a literature review. Australas Psychiatry 2005; 13: 54–59
   PubMedGoogle Scholar
• Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev 2007; 2: CD005594
   Google Scholar
• Haas J, Hill R, Krum H, et al. Clozapine-associated myocarditis. Drug Saf 2007; 30: 47–57
   PubMed Web of Science ®Google Scholar
• Clozapine and myocarditis. Aust Adv Drug Reac Bull 2007;26:3.
   Google Scholar
• Hagg S, Spigset O, Andrew B, Soderstrom T. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21: 382–388
   PubMed Web of Science ®Google Scholar
• Reinders J, Parsonage W, Lange D, Potter JM, Plever S. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004; 38: 915–922
   PubMed Web of Science ®Google Scholar
• Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–1845
   PubMed Web of Science ®Google Scholar
• Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 1997; 58: 341–347
   PubMed Web of Science ®Google Scholar
• Blanch J, Grimalt F, Massana G, Navarro V. Efficacy of olanzapine in the treatment of psychogenic excoriation. Br J Dermatol 2004; 157: 714–716
   Web of Science ®Google Scholar
• Arnold LM, McElroy SL, Mutasim DF, Dwight MM, Lamerson CL, Morris EM. Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry 1998; 59: 509–514
   PubMed Web of Science ®Google Scholar
• Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29: 1003–1006
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911–932
   PubMed Web of Science ®Google Scholar